Regulatory reporting: the post-deadline Annex IV health check for proactive AIFMs
5 questions to ask about your reporting process
.png?width=1200&height=628&name=AQM_Health%20Check_Annex%20IV%20Sales%20Campaign_Photo%20(2).png "AQM_Health Check_Annex IV Sales Campaign_Photo (2)")
The last AIFMD Annex IV deadline has passed, but the true measure of your reporting process isn't just about submission. It’s about efficiency, accuracy and preparedness. Why not use this checklist to evaluate your firm's current Annex IV reporting strategy and identify areas for improvement?
1. How much manual effort went into collecting and validating your data this cycle?
A. Hours of manual data aggregation and validation across disparate spreadsheets and systems.
B. A few days of work, with some data needing to be manually adjusted and reviewed.
C. Minimal manual effort, as data was automatically aggregated and validated by our system
2. How confident were you in the accuracy and completeness of your submitted data?
A. I was confident, but only after a significant manual review and cross-checking process.
B. It was difficult to be 100% certain; we often find small errors after submission.
C. I had complete confidence, with automated validation and a clear, auditable trail.
3. Does your current process provide real-time insight into your AIF's risk profile from the reporting data?
A. None. We compile the data for submission, and that's where its journey ends.
B. Limited insight. We can pull some reports, but it's not dynamic or real-time.
C. Full real-time insight. We leverage our reporting data for active risk analysis and strategic decisions.
4. How agile is your current setup to adapt to evolving regulatory requirements (e.g., AIFMD II)?
A. It would be a major project, requiring a new workflow and significant manual changes.
B. We could adapt, but it would require a lot of last-minute scrambling and stress.
C. We are already prepared. Our system is updated automatically to reflect new regulations.
5. Could your team's time spent on Annex IV be better allocated to strategic, value-adding activities?
A. Our team is completely diverted to compliance, taking away from their core roles.
B. It's a big distraction, but we manage to balance it with other duties.
C. The process is so streamlined that our team can focus on what truly drives our business forward.
.png?width=372&height=524&name=AQM_Annex%20IV_Health%20Check%20photo%20(1).png "AQM_Annex IV_Health Check photo (1)")